Pembrolizumab in Treating Patients With Malignant Mesothelioma
Public ClinicalTrials.gov record NCT02399371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma
Study identification
- NCT ID
- NCT02399371
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of Chicago
- Other
- Enrollment
- 65 participants
Conditions and interventions
Conditions
- Biphasic Mesothelioma
- Epithelioid Mesothelioma
- Peritoneal Malignant Mesothelioma
- Pleural Biphasic Mesothelioma
- Pleural Epithelioid Mesothelioma
- Pleural Malignant Mesothelioma
- Pleural Sarcomatoid Mesothelioma
- Recurrent Peritoneal Malignant Mesothelioma
- Recurrent Pleural Malignant Mesothelioma
- Sarcomatoid Mesothelioma
Interventions
- Laboratory Biomarker Analysis Other
- Pembrolizumab Biological
- Pharmacogenomic Study Other
Other · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 30, 2015
- Primary completion
- Mar 19, 2026
- Completion
- Mar 19, 2026
- Last update posted
- Jun 10, 2025
2015 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Chicago | Chicago | Illinois | 60637 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02399371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02399371 live on ClinicalTrials.gov.